1. Home
  2. USIO vs SPRO Comparison

USIO vs SPRO Comparison

Compare USIO & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Usio Inc.

USIO

Usio Inc.

SELL

Current Price

$2.82

Market Cap

83.5M

Sector

Finance

ML Signal

SELL

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

SELL

Current Price

$1.10

Market Cap

67.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
USIO
SPRO
Founded
1998
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.5M
67.0M
IPO Year
1999
2017

Fundamental Metrics

Financial Performance
Metric
USIO
SPRO
Price
$2.82
$1.10
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
★ $5.92
$5.00
AVG Volume (30 Days)
197.7K
★ 839.8K
Earning Date
11-11-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 111.81
EPS
★ 0.01
N/A
Revenue
$28,200,535.00
★ $66,802,000.00
Revenue This Year
$14.57
N/A
Revenue Next Year
$11.98
N/A
P/E Ratio
$285.50
★ N/A
Revenue Growth
12.69
★ 39.24
52 Week Low
$1.03
$1.08
52 Week High
$3.06
$3.08

Technical Indicators

Market Signals
Indicator
USIO
SPRO
Relative Strength Index (RSI) 56.50 41.51
Support Level $2.15 $1.10
Resistance Level $3.03 $1.28
Average True Range (ATR) 0.17 0.06
MACD 0.01 -0.01
Stochastic Oscillator 67.74 2.50

Price Performance

Historical Comparison
USIO
SPRO

About USIO Usio Inc.

Usio Inc is a cloud-based Fintech payment processor. The company serves multiple industry verticals with technology that facilitates payment acceptance and funds disbursement in a single, full-stack ecosystem. It provides payment acceptance through multiple payment methods, including payment facilitation, prepaid card, and electronic billing products and services to businesses, merchants, and consumers. The company's reportable operating segments are Output Solutions and Merchant Services, and these segments.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: